Merck KGaA, Pfizer win another quick FDA review for avelumab; WHO tries to spur more incentives for antibiotics R&D
→ Merck KGaA and its Big Pharma partner Pfizer have won another priority review of their checkpoint inhibitor avelumab. Following up on a speedy review win last November for in metastatic Merkel cell carcinoma, the companies say regulators will be just as fast covering their application for metastatic urothelial carcinoma (mUC) with disease progression on or after platinum-based therapy. The partners are competing with AstraZeneca for fourth place in the lineup to get a checkpoint out on the market. Merck, Bristol-Myers Squibb and Roche all got there first, but everyone’s scrambling to stake out as much territory as possible for a new market likely worth tens of billions of dollars.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.